Zentalis Pharmaceuticals is restructuring to support the late-stage development of its WEE1 inhibitor, azenosertib, which includes reducing its workforce by about 40% and incurring one-time costs of approximately $7.0 to $8.0 million in Q1 2025, while ensuring sufficient funds to operate into late 2027.